Ray continued, “We’re also delighted to recognize Martin and Greg’s contributions to Synthekine with their new roles. Martin’s deep insights into cytokine biology and immunology ended up instrumental to shaping the development of STK-012, our first-in-course alpha/beta biased IL-2. Its unique system expands the therapeutic index of IL-2, considered one https://httpswwwzosanopharmacomte90086.blogoscience.com/43066416/not-known-factual-statements-about-https-www-zosanopharma-com-technology